Neda Hashemi‐Sadraei

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients

Carmen M. Perrino, John N. Eble, Chia‐Sui Kao et al. · Human Pathology · 2019 · 48 citations · Full text

Medicine, Oncology, Pathology +10

HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer.

Jason R. Brown, Hristos Z. Kaimakliotis, William Kevin Kelly et al. · Journal of Clinical Oncology · 2023 · 25 citations

Medicine, Oncology, Pharmacology +17

Prolonged Response to Anti–PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden

Olumide B. Gbolahan, Neda Hashemi‐Sadraei, Bert H. O’Neil · Journal of the National Comprehensive Cancer Network · 2019 · 22 citations · Full text

Medicine, Immunology, Oncology +17

Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma

Neda Hashemi‐Sadraei, Olumide B. Gbolahan, Hai Salfity et al. · American Journal of Clinical Oncology · 2017 · 20 citations

Medicine, Oncology, Surgery +15